NCT06897202View on ClinicalTrials.gov

A Study to Evaluate the Efficacy and Safety of Once-Weekly MET097 in Adults With Obesity or Overweight and T2DM

PHASE2RecruitingINTERVENTIONAL
Enrollment

125

Participants

Timeline

Start Date

March 14, 2025

Primary Completion Date

April 30, 2026

Study Completion Date

June 30, 2026

Conditions
Obesity in DiabetesType 2 Diabetes Mellitus (T2DM)
Interventions
DRUG

MET097 Injection

MET097 is an ultra-long-acting, fully-biased analog of human GLP-1.

DRUG

Placebo

Sterile 0.9% (w/v) saline will be used as placebo treatment during the study.

Trial Locations (5)

30030

RECRUITING

Research Site 097202-001002, Decatur

31405

RECRUITING

Research Site 097202-001005, Savannah

33024

RECRUITING

Research Site 097202-001001, Hollywood

33613

RECRUITING

Research Site 097202-001003, Tampa

75234

RECRUITING

Research Site 097202-001010, Cincinnati

Sponsors

Lead Sponsor

Metsera
All Listed Sponsors
lead

Metsera

INDUSTRY